+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 100Years
All Genders
ID06711887

Long-term Open-Label Study Evaluating Ianalumab Treatment Withdrawal and Continuation in Adults With Lupus Nephritis Completing the SIRIUS-LN Core Study

Led by Novartis Pharmaceuticals · Updated on 2026-10-13

348

Participants Needed

51

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the long-term efficacy and safety of ianalumab treatment in adults with lupus nephritis who have completed the SIRIUS-LN core study. The study focuses on two groups patients who achieved complete or partial renal response and stopped study treatment, and those who continue or start open-label ianalumab because they did not meet response criteria or were already receiving it. This open-label extension can last up to six years. Participants are divided into two cohorts. Cohort 1 includes patients who responded to previous treatment and will withdraw from the study drug while continuing standard care, with the option to restart ianalumab if they experience renal flare. Cohort 2 includes patients who did not respond or were already on open-label ianalumab and will continue receiving this treatment during the extension. The study allows investigators to decide if continuing in the extension is beneficial for each participant. Throughout the study, participants will be monitored for kidney flare-ups, changes in immunosuppressive medication, adverse events, and the presence of antibodies against ianalumab. Assessments include safety and efficacy measures over up to six years, with the primary outcomes focusing on time to renal flare or adverse events depending on the cohort. Participants will have regular evaluations to track their health status and treatment effects during this period.

CONDITIONS

Brief Title

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here